Newsroom | Gilead - Gilead Sciences
Gilead Signs Royalty-Free Voluntary Licensing Agreements with Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries. September 12, 2024.
Gilead Sciences Announces Fourth Quarter and Full Year 2023 …
Feb 6, 2024 · HIV product sales increased 6% to $18.2 billion in the full year 2023 compared to 2022, primarily reflecting higher demand across treatment and prevention, in addition to higher average realized price and favorable channel inventory dynamics.
Gilead Sciences
For more than 35 years, we've been tackling some of the world’s greatest public health challenges. We've revolutionized HIV treatment and prevention, delivered a cure for hepatitis C and made advancements in therapies for viral diseases and certain cancers.
Gilead Sciences to Acquire MiroBio
Aug 4, 2022 · MiroBio’s lead investigational antibody, MB272, is a selective agonist of immune inhibitory receptor B- and T-Lymphocyte Attenuator (BTLA) and has entered Phase 1 clinical trials, with the first patient dosed earlier this week.
Gilead Sciences Announces Third Quarter 2022 Financial Results
Oct 27, 2022 · Third Quarter 2022 Financial Results. Total third quarter 2022 revenue decreased 5% to $7.0 billion compared to the same period in 2021, primarily due to lower Veklury® (remdesivir) sales, partially offset by increased sales in HIV and oncology products.
Gilead Provides Update on Phase 3 EVOKE-01 Study - Gilead …
Jan 22, 2024 · FOSTER CITY, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC).
Gilead’s Innovative HIV Treatment Research Pipeline ... - Gilead …
Mar 5, 2024 · In a recent Phase 1b study published in The Lancet HIV, the investigational combination of lenacapavir + teropavimab (GS-5423, TAB) + zinlirvimab (GS-2872, ZAB) demonstrated high efficacy and maintained virologic suppression for …
News Details - Gilead Sciences
Feb 2, 2023 · Fourth Quarter 2022 Financial Results. Total fourth quarter 2022 revenue of $7.4 billion increased 2% compared to the same period in 2021, primarily due to increased sales in Oncology, HIV and hepatitis C virus (“HCV”), partially offset by lower Veklury® (remdesivir) sales.
Gilead Sciences Expands Liver Portfolio With Acquisition of …
Feb 12, 2024 · The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) including pruritus, complements Gilead’s existing liver portfolio and aligns with its long-standing commitment …
Gilead Sciences Announces Second Quarter 2022 Financial Results
Total second quarter 2022 revenue increased 1% to $6.3 billion compared to the same period in 2021, primarily due to increased sales in HIV and oncology products, offset partially by decreased sales of Veklury® (remdesivir) and hepatitis C virus (“HCV”) products.
- Some results have been removed